These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37074396)

  • 1. Liraglutide and Exercise Synergistically Attenuate Vascular Inflammation and Enhance Metabolic Insulin Action in Early Diet-Induced Obesity.
    Liu J; Aylor KW; Liu Z
    Diabetes; 2023 Jul; 72(7):918-931. PubMed ID: 37074396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide prevents microvascular insulin resistance and preserves muscle capillary density in high-fat diet-fed rats.
    Chai W; Fu Z; Aylor KW; Barrett EJ; Liu Z
    Am J Physiol Endocrinol Metab; 2016 Sep; 311(3):E640-8. PubMed ID: 27436611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin prevents endothelial oxidative stress and microvascular insulin resistance during obesity development in male rats.
    Liu J; Aylor KW; Chai W; Barrett EJ; Liu Z
    Am J Physiol Endocrinol Metab; 2022 Mar; 322(3):E293-E306. PubMed ID: 35128961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
    Mashayekhi M; Nian H; Mayfield D; Devin JK; Gamboa JL; Yu C; Silver HJ; Niswender K; Luther JM; Brown NJ
    Diabetes; 2024 Jan; 73(1):38-50. PubMed ID: 37874653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile.
    Larsen AT; Gydesen S; Sonne N; Karsdal MA; Henriksen K
    BMC Endocr Disord; 2021 Jan; 21(1):10. PubMed ID: 33413317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide treatment improves the coronary microcirculation in insulin resistant Zucker obese rats on a high salt diet.
    Sukumaran V; Tsuchimochi H; Sonobe T; Waddingham MT; Shirai M; Pearson JT
    Cardiovasc Diabetol; 2020 Feb; 19(1):24. PubMed ID: 32093680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation-induced microvascular insulin resistance is an early event in diet-induced obesity.
    Zhao L; Fu Z; Wu J; Aylor KW; Barrett EJ; Cao W; Liu Z
    Clin Sci (Lond); 2015 Dec; 129(12):1025-36. PubMed ID: 26265791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial.
    Sandsdal RM; Juhl CR; Jensen SBK; Lundgren JR; Janus C; Blond MB; Rosenkilde M; Bogh AF; Gliemann L; Jensen JB; Antoniades C; Stallknecht BM; Holst JJ; Madsbad S; Torekov SS
    Cardiovasc Diabetol; 2023 Feb; 22(1):41. PubMed ID: 36841762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of liraglutide on dietary lipid-induced insulin resistance in humans.
    Koska J; Lopez L; D'Souza K; Osredkar T; Deer J; Kurtz J; Salbe AD; Harman SM; Reaven PD
    Diabetes Obes Metab; 2018 Jan; 20(1):69-76. PubMed ID: 28605158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial.
    Mashayekhi M; Beckman JA; Nian H; Garner EM; Mayfield D; Devin JK; Koethe JR; Brown JD; Cahill KN; Yu C; Silver H; Niswender K; Luther JM; Brown NJ
    Diabetes Obes Metab; 2023 Feb; 25(2):570-580. PubMed ID: 36306151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
    Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
    Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways.
    Zhou JY; Poudel A; Welchko R; Mekala N; Chandramani-Shivalingappa P; Rosca MG; Li L
    Eur J Pharmacol; 2019 Oct; 861():172594. PubMed ID: 31412267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.
    Somm E; Montandon SA; Loizides-Mangold U; Gaïa N; Lazarevic V; De Vito C; Perroud E; Bochaton-Piallat ML; Dibner C; Schrenzel J; Jornayvaz FR
    Transl Res; 2021 Jan; 227():75-88. PubMed ID: 32711187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of glucagon-like peptide-1 analog liraglutide on the systemic inflammation in high-fat-diet-induced mice.
    Sha S; Liu X; Zhao R; Qing L; He Q; Sun L; Chen L
    Endocrine; 2019 Dec; 66(3):494-502. PubMed ID: 31542859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide induces beige fat development and promotes mitochondrial function in diet induced obesity mice partially through AMPK-SIRT-1-PGC1-α cell signaling pathway.
    Zhou J; Poudel A; Chandramani-Shivalingappa P; Xu B; Welchko R; Li L
    Endocrine; 2019 May; 64(2):271-283. PubMed ID: 30535743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice.
    Jojima T; Uchida K; Akimoto K; Tomotsune T; Yanagi K; Iijima T; Suzuki K; Kasai K; Aso Y
    Atherosclerosis; 2017 Jun; 261():44-51. PubMed ID: 28445811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of WBN/Kob diabetic fatty rats supplemented with a fructose-rich diet as a metabolic syndrome model: response to a GLP-1 receptor agonist.
    Namekawa J; Nemoto S; Sunada G; Takanashi Y; Fujio S; Shirai M; Asai F
    J Vet Med Sci; 2018 Oct; 80(10):1515-1523. PubMed ID: 30175725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism.
    West JA; Tsakmaki A; Ghosh SS; Parkes DG; Grønlund RV; Pedersen PJ; Maggs D; Rajagopalan H; Bewick GA
    PLoS One; 2021; 16(3):e0249239. PubMed ID: 33788878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Globular adiponectin ameliorates metabolic insulin resistance via AMPK-mediated restoration of microvascular insulin responses.
    Zhao L; Fu Z; Wu J; Aylor KW; Barrett EJ; Cao W; Liu Z
    J Physiol; 2015 Sep; 593(17):4067-79. PubMed ID: 26108677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonists.
    Tanday N; Lafferty RA; Flatt PR; Irwin N
    Diabetes Obes Metab; 2022 Dec; 24(12):2353-2363. PubMed ID: 35848461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.